US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(CSE:
MDMA
)
0.2450
UNCHANGED
Delayed Quote
Updated: 2:33 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MDMA
< Previous
1
2
Next >
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023
PharmAla Biotech is the only company in the world with the ability to ship GMP MDMA and Psilocybin today
From
PharmAla Biotech
Via
GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
January 27, 2023
Via
ACCESSWIRE
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference
December 13, 2022
Company invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation
From
Virtual Investor Conferences
Via
GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
November 16, 2022
PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers
From
PharmAla Biotech
Via
GlobeNewswire
< Previous
1
2
Next >
